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Abstract 
Background: In Huntington’s Disease (HD) cognitive decline can occur before unequivocal motor signs become apparent. As cognitive decline 
often starts early in the course of the disease and has a progressive nature over time, cognition can be regarded as a key target for symptomatic 
treatment. The specific progressive profile of cognitive decline over time is unknown. 
Objective: The aim of this study is to quantify the progression of cognitive decline across all HD stages, from pre-motormanifest to advanced 
HD, and to investigate if CAG length mediates cognitive decline. 
Methods: In the European REGISTRY study 2,669 HD expansion gene carriers underwent annual cognitive assessment. General linear mixed 
models were used to model the cognitive decline for each cognitive task across all disease stages. Additionally, a model was developed to 
evaluate the cognitive decline based on CAG length and age rather than disease stage.  
Results: There was significant cognitive decline on all administered tasks throughout pre-motormanifest (close to estimated disease onset) 
participants and the subsequent motormanifest participants from stage 1 to stage 4. Performance on the Stroop Word and Stroop Color tests 
additionally declined significantly across the two pre-motormanifest groups: far and close to estimated disease onset.  
The evaluation of cognition performance in relation to CAG length and age revealed a more rapid cognitive decline in participants with longer 
CAG length than participants with shorter CAG length over time.  
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Conclusion: Cognitive performance already shows decline in pre-motormanifest HD gene expansion carriers and gradually worsens to late stage 
HD. HD gene expansion carriers with certain CAG length have their own cognitive profile, i.e. longer CAG length is associated with more rapid 
decline.  
Highlights: 
 Cognitive decline is mediated by CAG length in Huntington’s disease 
 Stroop Word and Color test are sensitive in tracking cognitive decline in HD 
 Cognitive decline starts early in the course of Huntington’s disease 
Keywords: Huntington’s Disease, cognition, longitudinal, REGISTRY 
 
Cognitive decline in HD 
3 
 
1.0 Introduction 
Huntington’s disease (HD) is an autosomal dominant inherited, progressive neurodegenerative disorder caused by a CAG repeat 
expansion in the huntingtin gene on chromosome 4 (The Huntington’s Disease Collaborative Research Group, 1993) and is characterized by 
motor and psychiatric symptoms, and cognitive decline. Typically, a formal clinical diagnosis of HD is based on the appearance of unequivocal 
motor signs (Roos, 2010). The importance of psychiatric symptoms and cognitive decline has become more recognized and new guidelines have 
been proposed, which include these signs for clinical diagnosis (Reilmann, Leavitt, & Ross, 2014). Still, these signs are insufficiently specified 
and to date it is arbitrary when these signs are disease specific and should be taken into consideration for a clinical diagnosis (Reilmann et al., 
2014).  
In the last decade, there has been a growing interest in the cognitive decline and many studies have focused on this aspect in HD. 
Nevertheless, there have been relatively few longitudinal studies to date to track the progression of cognitive functioning, and their results have 
been somewhat conflicting (Hart, Middelkoop, Jurgens, Witjes-Ane, & Roos, 2011; A.K. Ho et al., 2003; Lemiere, Decruyenaere, Evers-
Kiebooms, Vandenbussche, & Dom, 2004; Paulsen, Smith, Long, investigators, & Coordinators of the Huntington Study, 2013; Stout et al., 
2012; Witjes-Ane et al., 2003) which can be attributed to the diversity of study designs. The diversity in methodology is reflected in the selection 
of tasks administered, length of follow-up, sample size and characteristics of participant population. These different studies suggest that certain 
types of cognitive tasks are sensitive to particular stages of HD to track disease progression: simple psychomotor tasks have been shown to be 
particularly sensitive in the 5-10 years preceding motor symptoms onset (Dumas, van den Bogaard, Middelkoop, & Roos, 2013; Maroof, Gross, 
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& Brandt, 2011; J. S. Snowden, Craufurd, Thompson, & Neary, 2002; Solomon et al., 2008) whereas performance on tasks of memory and 
executive function appear to decline particularly around the time of clinical disease onset (Maroof et al., 2011; Montoya, Price, Menear, & 
Lepage, 2006; J. S. Snowden et al., 2002; Solomon et al., 2007). It has also been demonstrated that simple psychomotor tasks are more sensitive 
to use in longitudinal studies than more complex tasks of executive function in pre-motor manifest and early HD (Bachoud-Levi et al., 2001; 
A.K. Ho et al., 2003; J. Snowden, Craufurd, Griffiths, Thompson, & Neary, 2001). Thus far studies of cognition in HD over time have been 
limited to the study of pre-motormanifest and/or early HD. To our knowledge no studies have longitudinally examined cognition across all 
separate disease stages with a large sample size, which is essential to fully understand the natural course of cognitive decline in HD. It is 
important to know if specific cognitive domains gradually worsen over time or if, and when, floor and ceiling effects occur. This knowledge is 
particularly useful for future clinical trials targeting cognition, in order to evaluate the effectiveness of potential interventions in stopping or 
slowing down cognitive decline in HD. In HD it is known that CAG negatively influences disease progression, i.e. earlier disease onset with 
longer CAG length (Penney, Vonsattel, MacDonald, Gusella, & Myers, 1997). As cognitive decline is associated with brain atrophy (Bohanna, 
Georgiou-Karistianis, Hannan, & Egan, 2008; Montoya et al., 2006), which in turn is also negatively influenced by CAG length (Penney et al., 
1997), it is of interest to investigate if CAG length also mediates cognitive deterioration. If indeed CAG influences cognitive decline this could 
help to explain why HD gene carriers develop cognitive deficits at different ages. From a clinical point of view this could raise more awareness 
that certain individuals have a higher risk at developing early cognitive deficits. Additionally, this information can be used to inform the design 
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of future trials, e.g. in defining the study population or to determine whether expensive MRI protocol is necessary or if cognitive tasks would be 
sufficient.  
In 2004 the European Huntington’s Disease Network (EHDN) launched the observational REGISTRY study (Orth et al., 2011), in which 
HD expansion gene carriers undergo annual assessment of motor function, cognition, behavior, and day-to-day functioning. After years of 
longitudinal data collection, the REGISTRY study provides the opportunity to explore cognitive change across all HD stages. The aim of this 
study is to evaluate the progression of cognitive decline in HD throughout the disease stages, from pre-motormanifest to advanced HD, and to 
evaluate if CAG length mediates cognitive decline. The second aim is to assess whether the individual cognitive tasks are efficacious for 
measuring cognitive decline across all disease stages or if the task sensitivity is disease stage specific. 
 
 2.0 Methods 
 Data was acquired from the European, multicenter, longitudinal, observational REGISTRY study which was conducted in 17 countries. 
All participating sites acquired ethical approval before conducting the study and all participants gave written informed consent. Study 
assessments were administered by trained professionals and all data was monitored. For a full description of the study, see Orth et al. (Orth et al., 
2011). 
 
2.1 Participants 
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 By April 2014, a total of 2,815 participants met the criteria for the requested data cut; i.e. all participants with confirmed CAG length 
expansion of ≥ 36 and cognitive assessment. After receiving the data cut, only participants with CAG length between 38 and 50 (both inclusive) 
and visits of participants with age between 25 and 80 (both inclusive) at time of assessment were included in the analysis. Resulting in a total of 
2,669 participants for analysis with a mean of 3.7 annual visits, ranging from one to 12 visits per participants (table 1). 
 Participants were defined as pre-motormanifest if their total motor score on the Unified Huntington’s Disease Rating Scale (UHDRS) 
was less than or equal to five, indicating no substantial motor signs. This pre-motormanifest group was further divided into a group which is far 
from estimated disease onset (preA) and a group which is close to estimated disease onset (preB), split at the median of the estimated disease 
onset (median: 13.3 years) according to the formula developed by Langbehn and colleagues (D.R. Langbehn, Brinkman, Falush, Paulsen, & 
Hayden, 2004; D. R. Langbehn, Hayden, Paulsen, & Group, 2010; Tabrizi et al., 2009; Wild, 2013). The manifest participants were divided into 
the five disease stages as defined by Shoulson et al. (Shoulson & Fahn, 1979), using the total function capacity scale of the UHDRS.   
 
2.2 Assessments 
 All participants were clinically assessed on an annual basis with a time window of ± three months. The time window was not strictly 
enforced and it was possible to assess participants outside their time window or even miss annual visits without exclusion of the study.  
The REGISTRY cognitive battery consisted of the UHDRS’ cognitive tasks: Phonemic Verbal Fluency (total number correct in three 
minutes), the three conditions of the  Stroop-Color-Word-Interference task: word reading, color naming and interference condition (total number 
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correct within 45 seconds for each condition), and Symbol Digit Modalities task (total number correct in 90 seconds) (Huntington Study Group, 
1996). In 2010, the Categorical Fluency task was added to the cognitive battery (total number correct in one minute) (A. K. Ho et al., 2002). On 
each task a higher numerical score indicates higher cognitive performance. These raw cognitive scores at each visit were used for the statistical 
analysis.  
 Depression was assessed by means of the behavior assessment of the UHDRS (Huntington Study Group, 1996) or the Problem Behavior 
Assessment – short version (PBA-s) (Callaghan et al., 2015). 
 Medication use was also recorded as part of the REGISTRY study; medications with possible influence on cognitive performance were 
grouped into the following categories: benzodiazepine, antidepressant, antipsychotic, atypical antipsychotic, anticonvulsant, opioids, 
antiparkinsonian and others.  
  
2.3 Statistical analysis 
 A linear mixed models analysis was used because it allows for varying time windows, an unequal number of visits and missing values 
(Gibbons, Hedeker, & DuToit, 2010). Two models were designed to understand the progressive nature of cognitive decline in HD.  
First, change over time in performance on the cognitive tasks as a function of disease stage was analyzed, adjusting for depressive mood, 
sex, years of education, medication use, study site and third order polynomial function of age. The results of this longitudinal model were used to 
analyze if group differences were present in rate of cognitive decline by disease stage. Per task it was analyzed if there was a significant 
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difference in cognitive performance between one stage and the subsequent stage; e.g. significant difference between disease stage 1 and disease 
stage 2. It is important to note, as participants came in for testing over several years, it was common that participants progressed from one 
disease stage to the next. In order to compare cognitive performance between disease stages participants were allowed to transfer into the next 
category of disease stage on a subsequent visit dates to maintain homogenous groups.  
The second model assessed change over time in performance on the cognitive tasks as a function of CAG length and third order 
polynomial function of age, adjusting for depression, sex, years of education, medication use, and study site. Per task it was analyzed if there 
was a significant difference in cognitive performance between different CAG lengths for a certain age. For this between group comparison 
subsequent CAG lengths are compared to each other by steps of 2 (from CAG length 38 to 48) at certain ages (30, 45, 60). For example, task 
performance of participants with CAG lengths of 38 and 40 was compared for ages 30, 45, and 60.   
For both models multiple testing was performed and therefore a conservative significance level was used: p = 0.05 divided by the number 
of performed tests (i.e. either p = 0.008 or 0.01). 
 
 3.0 Results 
 The baseline characteristics are presented in table 1. The seven groups differed significantly from each other on the following variables: 
age (F(6, 2662) = 124.86, p < 0.01), years of education (F(6,2524) = 23.08, p < 0.01), CAG length (F(6, 2662) = 37.89, p < 0.01), and gender 
χ²(6) = 42.56, p <0.01).  
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3.1 Cognitive task performance based on disease stage 
For this section, the data was longitudinally modelled in order to assess group differences (i.e. disease stage) as described in the methods 
section. Performance on all cognitive tasks declined throughout the different groups (see figure 1). As participants progressed from preA to stage 
5 the cognitive performance of the Stroop Word Test declined most rapidly. More precisely, performance on the Stroop Word Test decreased on 
average by 7.5 correct answers from one group to the subsequent group: preA scored significantly higher than the preB group (b = 5.35, 
t(7895.31) = 5.52, p < 0.01). PreB was able to read on average seven more words than stage 1 (t(7849.43) = 9.85, p < 0.01). Stage 1 scored 
significantly better on the Stroop Word test than stage 2 (b = 8.34, t(7524.45) = 18.71, p < 0.01). Comparing stage 2 with stage 3, the former 
showed a significantly better performance (b = 9.60, t(7366.26) = 22.67, p < 0.01). Stage 3 was able to read 8 more words within the time frame 
than stage 4 (t(7139.92) = 11.90, p < 0.01). There was a non-significant trend towards better performance on the Stroop Word test in stage 4 than 
stage 5 (b = 7.50, t(6924.37) = 3.40, p < 0.05).  
In contrast to the results of the Stroop Word Test, no pronounced and rapid decline in cognitive performance of the Phonemic Verbal 
Fluency Test was found. Task performance on the Phonemic Verbal Fluency Test was similar for the PreA and PreB groups (b = 1.66, 
t(8340.90) = 3.03, p > 0.05) as well as for stage 4 and 5 (b = 0.39, t(6871.93) = 0.28, p > 0.05). Throughout preB to stage 4 there was a decline 
by on average three correct responses. This decline was statistically significant (see table 2), but the slope of the decline was relatively flat (see 
figure 1), i.e. the Phonemic Verbal Fluency Test showed no pronounced discrimination between the disease stages.  
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The results of the other administered tasks were somewhere in between the results of the Stroop Word Test and the Phonemic Verbal 
Fluency test:  there was a significant difference in cognitive performance between all disease stages on the Stroop Color Test (table 2) but the 
slope for decline was less steep for the Stroop Color Test than for the Stroop Word Test (figure 1). Significant difference on performance on the 
Stroop Interference Test and the Symbol Digit Modalities Test was found between all disease stages except between stage 4 and 5 (table 2); i.e., 
the slope flattens at the end.  The same result was found for the Categorical Verbal Fluency Test, but overall the decline was less pronounced 
than for the Stroop Interference and the Symbol Digit Modalities test.  
 
3.2 Cognitive task performance based on CAG length and age 
For this section, the data was longitudinally modelled according to the second described model in the methods section, and these results 
were used to compare cognitive performance between different CAG length for certain ages. Here we only display the comparison on Stroop 
Word test performance between CAG length of 42 and CAG length of 44 at three different ages. Due to the chosen model with interaction 
between CAG lengths and a third order polynomial function of age the group comparison of the other CAG lengths for this test revealed the 
same results at these ages; i.e. if the distance between two CAG lengths is the same then the distance between the cognitive performance is the 
same as well.  
Task performance on the Stroop Word Test was mediated by CAG length and age; i.e. participants with a higher CAG length showed a 
more rapid decline than participants with a lower CAG length over time, see figure 2. Differences on task performance between CAG length 42 
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and 44 increased as a function of age. More precisely, performance on the Stroop Word Test was significantly higher for participants with a 
CAG length of 42 than for participants with CAG length of 44 at age 30 (b = 5.09, t(3831.8) = 10.25, p < 0.01). The score on the Stroop Word 
Test was 12 points higher for participants with CAG length of 42 compared to participants with CAG length of 44 at age 45 (t(3674.51) = 32.57, 
p < 0.01). At age 60 participants with a CAG length of 42 scored significantly higher than participants with CAG length of 44 (b = 16.03, 
t(3870.75) = 26.9, p < 0.01).  
 In contrast to the Stroop Word Test the Categorical Verbal Fluency Test did not discriminate well between the different CAG lengths. As 
participants aged the performance worsened but the different lines stay close to each other (see figure 2). For the Stroop Color Test, Strop 
Interference Test, Symbol Digit Modalities Test and Phonemic Verbal Fluency test significant different was found for all CAG comparisons at 
age 30, 45, 60. Figure 2 shows that for these tasks the separate lines stayed closer together than for the Stroop Word Test. The results for all 
cognitive tasks are presented in table 4 and figure 2. 
 
 4.0 Discussion 
 This current study evaluates the progression of cognitive decline in HD, from pre-motormanifest to late stage. Performance on the 
REGISTRY cognitive battery significantly worsened as HD progressed from preA to disease stage 4 with the exception of the Phonemic Verbal 
Fluency Test in the pre-motormanifest phase (i.e. no significant difference between preA and preB). The early decline of the other five cognitive 
tasks supports the notion that cognitive decline starts early in the disease process and even proceeds overt motor signs (Maroof et al., 2011; 
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Paulsen et al., 2013; J. S. Snowden et al., 2002; Solomon et al., 2008). By direct comparison of the cognitive tasks, taking into consideration the 
clinical relevance of decline, we demonstrated that the Stroop Word and Stroop Color Test are the most sensitive of the REGISTRY battery in 
discriminating between the different disease stages. These findings are supported by previous observations that the Stroop Word and Stroop 
Color Test are sensitive in pre-motormanifest (Paulsen et al., 2013) and early HD (Tabrizi et al., 2013). We have now demonstrated that this 
remains so over the disease course and that these tasks remain sensitive in later stages of HD. These results are in line with suggestions of 
previous studies that simple psychomotor tasks are the most appropriate to use in longitudinal research in HD (Bachoud-Levi et al., 2001; A.K. 
Ho et al., 2003; J. Snowden et al., 2001). This information is particularly useful for clinical trials as cognition is seen as a key target for 
symptomatic treatment.  
It has been argued that because the Stroop Word test and Stroop Color test have high linguistic demands they should not be included in 
test batteries for HD as clinical trials rely heavily on multicenter research across several countries (Stout et al., 2014). Nevertheless, the 
REGISTRY study was conducted in several countries with different languages and with correcting for study site we conclude that these tasks are 
sensitive in tracking psychomotor speed across multilingual HD populations. Additionally, these tasks are relatively easy to administer, efficient, 
and do not require fine motor skills. Therefore, we would strongly recommend to include the Stroop Word and Stroop Color test in HD clinical 
trials. All cognitive tasks showed a floor effect from disease stage 4 to disease stage 5; i.e. none of the tasks discriminated between these two 
stages. This illustrates that it is difficult to identify cognitive tasks in advanced HD, because of the severe cognitive deterioration in this stage.  
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To our knowledge no study has identified a suitable cognitive task for late stage HD. It is a challenge to administer cognitive tasks in this patient 
group because many patients are not able to write or speak anymore. 
A challenge when analyzing data with the most commonly examined disease stages is that no one continuous variable is used for 
defining all groups but rather different variables are used for defining pre-motormanifest groups and motormanifest groups. For the later the total 
functional capacity score (TFC) is used, however, the inter rater reliability of this scale is unknown, which could be challenging for multi-center 
studies. Therefore, we chose to also evaluate the data in a different way. It is known that CAG length influences disease progression; longer 
CAG length indicates earlier disease onset and faster disease progression (Andrew et al., 1993).  Therefore, we plotted cognitive performance in 
relation to CAG length and age. These patient characteristics are objective and therefore more suitable variables than disease stage to investigate 
the natural course of cognitive decline in HD. This approach revealed that participants with a certain CAG length follow their own cognitive 
performance curve: Individuals with a longer CAG length show a more rapid cognitive decline as individuals with a shorter CAG length. This is 
in line with the findings from Paulsen et al. (Paulsen et al., 2013) in the pre-motormanifest group. The results in general support that CAG length 
highly influences disease progression (Andrew et al., 1993), including cognitive decline. More precisely, the relationship between CAG length 
and cognitive decline over time was most pronounced for tasks of psychomotor function, i.e. Stroop Color and Stroop Word Test, rather than 
tasks relying on executive function, i.e. Stroop Interference and Phonemic Verbal Fluency Test. A possible explanation for the greater sensitivity 
of psychomotor tasks is that the role of the striatum is reflected in execution of these more automated tasks (J. Snowden et al., 2001; Thompson 
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et al., 2010). As the striatum starts to degenerate early in the course of HD (Vonsattel et al., 1985) it seems logical that functions relying on the 
involvement of the nucleus caudate decline early on and are progressive in HD, such as psychomotor speed. 
A limitation of this study was that REGISTRY was not designed to thoroughly capture cognitive decline in HD but rather to map disease 
progression of several domains in HD including cognition. As the REGISTRY study was designed to include also moderate to advanced HD 
patients the cognitive battery was rather short. We acknowledge that other studies purely focusing on cognition in HD have utilized a wider 
range of cognitive tasks (Stout et al., 2014). However, given the large sample size available, representing all stages of disease across multiple 
sites and countries, our results provide a valuable contribute to the understanding of cognitive decline in HD. 
Another limitation is that no control group with annual cognitive testing was available in the REGISTRY database. Thus, we were not 
able to compare the cognitive decline in HD to a control group population. Another challenge of the REGISTRY database was that a large 
number of participants were included and small differences between groups can result in statistical significant differences with large sample size. 
Therefore, we also evaluated if the cognitive decline was clinical relevant: for example we have found a statistical significant decline for the 
phonemic verbal fluency test but evaluated a decline of on average three points as not clinically relevant and concluded that this task does not 
discriminate sufficiently between the different groups.  
In conclusion, cognitive performance is negatively influenced by longer CAG length and worsens with age. The Stroop Word and Stroop 
color test are sensitive in tracking psychomotor speed in HD in all stages and we recommend inclusion of these tasks in cognitive batteries for 
clinical trials.  
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Eike Spruth, Silvia Thiel 
Bochum (Huntington-Zentrum (NRW) Bochum im St. Josef-Hospital):  Jürgen Andrich, Gisa Ellrichmann, Lennard Herrmann, Rainer 
Hoffmann, Barbara Kaminski, Peter Kraus, Carsten Saft, Christiane Stamm 
Dinslaken (Reha Zentrum in Dinslaken im Gesundheitszentrums Lang): Herwig Lange, Robert Maiwald 
Dresden (Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Klinik und Poliklinik für Neurologie): 
Cecile Bosredon, Ulrike Hunger, Matthias Löhle, Antonia Maass, Christiana Ossig, Simone Schmidt, Alexander Storch, Annett Wolz, Martin 
Wolz  
Erlangen (Universitätsklinikum Erlangen, Molekulare Neurologie und Klinik für Neurologie): Zacharias Kohl, Christina Kozay, Jasmin 
Ullah, Jürgen Winkler 
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Freiburg (Universitätsklinik Freiburg, Neurologie): Ulrike Bergmann, Regina Böringer, Philipp Capetian, Gerit Kammel, Johann Lambeck, 
Miriam Mächtel, Simone Meier, Michel Rijntjes, Birgit Zucker  
Hamburg (Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Neurologie): Kai Boelmans, Christos Ganos, Ines 
Goerendt, Walburgis Heinicke, Ute Hidding, Jan Lewerenz, Alexander Münchau, Michael Orth, Jenny Schmalfeld, Lars Stubbe, Simone Zittel 
Hannover (Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover): Gabriele Diercks, Dirk Dressler, 
Flverly Francis, Sabine Gayde-Stephan, Heike Gorzolla, Bianca Kramer, Rebecca Minschke, Christoph Schrader, Pawel Tacik  
Itzehoe (Schwerpunktpraxis Huntington, Neurologie und Psychiatrie): Michael Ribbat+  
Marburg KPP (Klinik für Psychiatrie und Psychotherapie Marburg-Süd): Bernhard Longinus 
Marburg UNI (Universitätsklinik Marburg, Sprechstunde für choreatiforme Bewegungsstörungen): Carsten Möller, Katrin Bürk 
München (Huntington-Ambulanz im Neuro-Kopfzentrum - Klinikum rechts der Isar der Neurologischen Klinik und Poliklinik der 
Technischen Universität München): Antje Lüsebrink, Mark Mühlau, Alexander Peinemann, Michael Städtler, Adolf Weindl, Juliane 
Winkelmann, Cornelia Ziegler  
Münster (Universitätsklinikum Münster, Klinik und Poliklinik für Neurologie): Natalie Bechtel, Heike Beckmann, Stefan Bohlen, Nicole 
Göpfert, Eva Hölzner, Herwig Lange, Ralf Reilmann, Stefanie Rohm, Silke Rumpf, Christian Sass, Sigrun Schepers, Nathalia Weber  
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Taufkirchen (Isar-Amper-Klinikum - Klinik Taufkirchen (Vils)): Michael Bachmeier, Matthias Dose, Nina Hofstetter, Ralf Marquard, 
Alzbeta Mühlbäck   
Ulm (Universitätsklinikum Ulm, Neurologie): Katrin Barth, Andrea Buck, Julia Connemann, Daniel Ecker, Carolin Geitner, Christine Held, 
Andrea Kesse, Bernhard Landwehrmeyer, Franziska Lezius, Jan Lewerenz, Solveig Nepper, Anke Niess, Michael Orth, Ariane Schneider, 
Daniela Schwenk, Sigurd Süssmuth, Sonja Trautmann, Melanie Vogel, Patrick Weydt  
 
ITALY 
Bari (Neurophysiopathology of Pain Unit, Basic Medical, Neuroscience and Sensory System Department, University of Bari): Claudia 
Cormio, Olimpia Difruscolo, Giovanni Franco, Vittorio Sciruicchio, Claudia Serpino, Marina de Tommaso 
Bologna (DIBINEM - Alma Mater Studiorum - Università di Bologna, IRCCS Istituto delle Scienze Neurologiche di Bologna): Giovanna 
Calandra-Buonaura, Sabina Capellari, Pietro Cortelli, Roberto Gallassi, Roberto Poda, Cesa Scaglione  
Florence (Department of Neuroscience, University of Florence & Careggi University Hospital): Elisabetta Bertini, Caterina Bartoli, 
Fernanda Fortunato, Elena Ghelli, Andrea Ginestroni, Claudia Mechi, Marco Paganini, Silvia Piacentini, Silvia Pradella, Anna Maria Romoli, 
Sandro Sorbi  
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Genoa (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova): 
Giovanni Abbruzzese, Monica Bandettini di Poggio, Giovanna Ferrandes, Paola Mandich, Roberta Marchese, Emilio Di Maria  
Milan (SODS Genetica delle Malattie Neurodegenerative e Metaboliche & U.O. Neurologia, Fondazione IRCCS Istituto Neurologico 
Carlo Besta): Alberto Albanese, Simona Castagliuolo, Anna Castaldo, Stefano Di Donato, Daniela Di Bella, Cinzia Gellera, Silvia Genitrini, 
Caterina Mariotti, Daniela Monza, Lorenzo Nanetti, Marta Panzeri, Dominga Paridi, Paola Soliveri, Francesca Spagnolo, Franco Taroni, Chiara 
Tomasello 
Naples (Department of Neurosciences and Reproductive and Odontostomatological Sciences, Federico II University of Naples): Giuseppe 
De Michele, Luigi Di Maio, Carlo Rinaldi, Marco Massarelli, Silvio Peluso, Alessandro Roca, Cinzia Valeria Russo, Elena Salvatore, Pierpaolo 
Sorrentino, Tecla Tucci 
Pozzilli (IS) (IRCCS Neuromed): Milena Cannella, Valentina Codella, Francesca De Gregorio, Annunziata De Nicola, Francesca Elifani, 
Tiziana Martino, Francesca Lovo, Irene Mazzante,  Martina Petrollini, Maria Simonelli, Ferdinando Squitieri, Maurizio Vezza 
Rome (LIRH Foundation): Barbara D'Alessio, Chiara Esposito, Irene Mazzante, Ferdinando Squitieri 
Rome (Department of Neurology, Università Cattolica del Sacro Cuore; Institute of Translational Pharmacology & Institute of 
Cognitive Sciences and Technologies, National Research Council of Italy):  Anna Rita Bentivoglio, Francesco Bove,  Claudio Catalli, 
Raffaella Di Giacopo, Alfonso Fasano, Marina Frontali, Arianna Guidubaldi, Tamara Ialongo, Gioia Jacopini, Giovanna Loria, Anna Modoni, 
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Martina Petracca, Carla Piano, Piccininni Chiara, Davide Quaranta, Silvia Romano, Francesco Soleti, Marcella Solito, Maria Spadaro, Flavia 
Torlizzi, Paola Zinzi 
Rome (Azienda Ospedaliera Sant'Andrea; Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of 
Medicine and Psychology, Sapienza University of Rome; Institute of Translational Pharmacology & Institute of Cognitive Sciences and 
Technologies, National Research Council of Italy): Giulia Coarelli, Michela Ferraldeschi, Marina Frontali, Gioia Jacopini, Giovanni Ristori, 
Silvia Romano, Paola Zinzi 
 
NETHERLANDS 
Enschede (Medisch Spectrum Twente): Monique S.E. van Hout, Jeroen P.P. van Vugt, A. Marit de Weert, Marloes Verhoeven 
Groningen (Polikliniek Neurologie): Meike Dekker, Nico Leenders, Joost van Oostrom, Jesper Klooster, Berry Kremer  
Leiden (Leiden University Medical Centre (LUMC)): Verena Baake, Simon J. A. van den Bogaard, Reineke Bos, Eve M. Dumas, Ellen P. ‘t 
Hart, Anne Kampstra, Raymund A.C. Roos, Anne Schoonderbeek 
Maastricht: Annelien Duits, Mayke Oosterloo, Mirella Waber 
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NORWAY 
Bergen (Haukeland University Hospital, Dept of Medical Genetics and Olaviken Psychiatric Hospital): Ellen Økland Blinkenberg. (NKS 
Olaviken`s HD clinic): Erik Hauge, Hilde Tyvoll 
Oslo University Hospital (Dept. of Medical Genetics, Dept. of Neurology, Dept.of Neurorehabilitation): Olaf Aaserud, Nils Olaf Aanonsen, 
Kathrine Bjørgo, Nancy Borgeød, Elisabeth Dramstad, Madeleine Fannemel, Jan C. Frich, Per F. Gørvell, Kathrine Haggag, Cecilie Haggag 
Johannessen, Arvid Heiberg, Lars Retterstøl, Oddveig Røsby, Jutta Rummel, Alma Sikiric, Bodil Stokke, Marleen van Walsem, Ragnhild 
Wehus 
Trondheim (St. Olavs Hospital): Inga Bjørnevoll, Sigrid Botne Sando, Marte Gjøl Haug, Hanna Haugan Størseth, Vibeke Arntsen  
 
POLAND 
Gdansk (St. Adalbert Hospital, Gdansk, Medical University of Gdansk, Neurological and Psychiatric Nursing Dpt.): Artur Dziadkiewicz, 
Agnieszka Konkel, Ewa Narożańska, Malgorzata Nowak, Piotr Robowski, Emilia Sitek, Jaroslaw Slawek, Witold Soltan, Michal Szinwelski 
Katowice (Medical University of Silesia, Katowice): Michał Arkuszewski, Magdalena Błaszczyk, Magdalena Boczarska-Jedynak, Ewelina 
Ciach-Wysocka, Agnieszka Gorzkowska, Barbara Jasińska-Myga, Aleksandra Kaczmarczyk, Gabriela Kłodowska – Duda, Grzegorz Opala, 
Monika Rudzińska, Daniel Stompel  
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Krakow (Krakowska Akademia Neurologii): Krzysztof Banaszkiewicz, Dorota Boćwińska, Kamila Bojakowska-Jaremek, Małgorzata Dec, 
Natalia Grabska, Malgorzata Krawczyk, Ewelina Kubowicz, Michalina Malec-Litwinowicz, Monika Rudzińska, Agata Stenwak, Andrzej 
Szczudlik, Elżbieta Szczygieł, Magdalena Wójcik, Anna Wasielewska  
Poznan (Poznan University of Medical Sciences, Poland): Jacek Anioła Anna Bryl, Anna Ciesielska, Aneta Klimberg, Jerzy Marcinkowski, 
Husam Samara, Justyna Sempołowicz, Bartłomiej Wiśniewski, Daniel Zielonka 
Warsaw-MU (Medical University of Warsaw, Neurology): Anna Gogol (formerly Kalbarczyk), Piotr Janik, Zygmunt Jamrozik, Anna 
Kaminska, Hubert Kwiecinski+, Natalia Szejko 
Warsaw-IPiN (Institute of Psychiatry and Neurology Dep. of Genetics, First Dep. of Neurology): Jakub Antczak, Katarzyna Jachinska, 
Wioletta Krysa, Maryla Rakowicz, Przemyslaw Richter, Rafal Rola, Danuta Ryglewicz, Halina Sienkiewicz-Jarosz, Iwona Stępniak, Anna 
Sułek, Grzegorz Witkowski, Jacek Zaremba, Elzbieta Zdzienicka, Karolina Ziora-Jakutowicz 
 
PORTUGAL 
Coimbra – (Hospital Universitário de Coimbra): Cristina Januário, Filipa Júlio 
Lisbon-HSM (Hospital de Santa Maria, Clinical Pharmacology Unit, Instituto de Medicina Molecular): Leonor Correia Guedes, Miguel 
Coelho, Joaquim J Ferreira, Tiago Mestre, Tiago Mendes, Anabela Valadas  
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Porto-HGSA (Hospital Santo António- Centro Hospitalar do Porto): Gonçalo Cação, Sara Cavaco, Joana Damásio, Joana Fernandes, Rui 
Loureiro, Inês Moreira, Marina Magalhães,  
Porto- HSJ (Hospital de São João): Carlos Andrade, Andreia Costa, Carolina Garrett, Miguel Gago, Joana Guimarães, João Massano, Joana 
Meireles, Ana Monteiro  
 
SPAIN 
Badajoz (Hospital Infanta Cristina): Carmen Durán Herrera, Patrocinio Garcia Moreno 
Barcelona-Bellvitge (Hospital Universitari de Bellvitge): Jordi Bas, Núria Busquets, Matilde Calopa, Serge Jaumà Classen, Nadia Rodríguez 
Dedichá 
Barcelona- Clínic i Provincial (Hospital Clínic i Provincial): María Teresa Buongiorno, Andrés de la Cerda Santa María, Esteban Muñoz, 
Pilar Santacruz 
Barcelona-Hospital Mútua de Terrassa: Miquel Aguilar Barbera, Ana Rojo Sebastián, Sonia Arribas Pardo, Dolors Badenes Guia, Noemi 
Calzado, Laura Casas Hernanz, Juan Pablo Tartari Díaz-Zorita, Judit López Catena, Pilar Quiléz Ferrer, Gemma Tome Carruesco 
Barcelona-Merced (Hospital Mare de Deu de La Merced): Misericordia Floriach Robert, Cèlia Mareca Viladrich, Elvira Roca, Jesús Miguel 
Ruiz Idiago, Antonio Villa Riballo 
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Barcelona-Santa Cruz y San Pablo (Hospital de la Santa Creu i Sant Pau): Antonia Campolongo, Ramon Fernandez de Bobadilla, Jaime 
Kulisevsky Bojarsky, Saul Martinez-Horta, Javier Pagonabarraga, Jesus Perez Perez, Roser Ribosa, Carolina Villa 
Burgos (Servicio de Neurología Hospital General Yagüe): Esther Cubo, Cecilia Gil Polo, Natividad Mariscal 
Canarias (Hospital Insular de Gran Canaria): Sandra Gutierrez Romero, José Matías Arbelo, Rocío Malo de Molina, Idaira Martín, Juan 
Manuel Periañez, Beatriz Udaeta 
Fuenlabrada (Hospital Universitario): Fernando Alonso-Frech, María del Valle Loarte 
Granada (Hospital Universitario San Cecilio, Neurología): Francisco Barrero, Blas Morales 
Madrid-BTCIEN (Fundación CIEN): Belén Frades, Marina Ávila Villanueva, Maria Ascension Zea Sevilla 
Madrid-Clinico (Hospital Clínico Universitario San Carlos): Fernando Alonso Frech, María del Mar Fenollar, Rocío García-Ramos García, 
Clara Villanueva  
Madrid RYC (Hospital Ramón y Cajal, Neurología): Mónica Bascuñana, Marta Fatás Ventura, Juan García Caldentey, Guillermo García 
Ribas, Justo García de Yébenes, José Luis López–Sendón Moreno, Verónica Mañanes Barral, Patricia Trigo Cubillo  
Madrid FJD (Madrid-Fundación Jiménez Díaz): Cici Feliz Feliz, Pedro José García Ruíz, Ana García, Juan García Caldentey, Rosa Guerrero 
López, Antonio Herranz Bárcenas, Asunción Martínez-Descals, Veronica Puertas Martin, Noelia Rodríguez Martínez, María José Sainz Artiga, 
Vicenta Sánchez, Angel Martínez Pueyo, Javier del Val Fernandez 
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Murcia (Hospital Universitario Virgen de la Arrixaca): Moreau María Dolores Alarcón, Carmen Antúnez Almagro, Esther Diéguez, Lorenza 
Fortuna, Salvadora Manzanares, Juan Marín Muñoz, María Martirio Antequera Torres, Fuensanta Noguera Perea, Laura Vivancos  
Oviedo (Hospital Central de Asturias): Sonia González, Luis Menéndez Guisasola, Marta Para Prieto, René Ribacoba, Carlos Salvador, Pablo 
Sánchez Lozano 
Palma de Mallorca (Hospital Universitario Son Espases): Juan García Caldentey, Aránzazu Gorospe, Inés Legarda Ramirez, Penelope Navas 
Arques, Monica Rodriguez Lopera, Barbara Vives Pastor 
Pamplona (Complejo Hospitalario de Navarra): Itziar Gaston, Fermin Garcia-Amigot, Maria Dolores Martinez-Jaurrieta, Maria Antonia 
Ramos-Arroyo 
Sevilla (Hospital Virgen Macarena): Fátima Damas Hermoso, José Manuel García Moreno, Carolina Mendez Lucena, Eva María Pacheco 
Cortegana, José Chacón Peña, Luis Redondo, Violeta Sánchez Sánchez  
Valencia (Hospital la Fe): Maria Bosca, Juan Andres Burguera, Francisco Castera Brugada Carmen Peiró Vilaplana, Pilar Solís,  Begoña 
Jeweinat Figuerola, Paloma Millan Palanca  
 
SWEDEN 
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Göteborg (Sahlgrenska University Hospital): Maria Berglund, Peter Berglund, Radu Constantinescu, Gunnel Fredlund, Ulrika Høsterey-
Ugander, Kajsa Lewin, Petra Linnsand, Liselotte Neleborn-Lingefjärd, Jan Wahlström+ 
Lunds University Hospital: Åsa Petersén, Jan Reimer, Håkan Widner  
Umeå (Umeå University Hospital): Måns Berglund, Ghada Loutfi, Carina Olofsson, Eva-Lena Stattin, Laila Westman, Birgitta Wikström 
Uppsala University Hospital: Camilla Ekwall, Marie-Lousie Göller, Valter Niemelä, Jimmy Sundblom  
 
SWITZERLAND 
Bern: Jean-Marc Burgunder, Yanik Stebler (Swiss HD Zentrum),  Alain Kaelin, Irene Romero, Michael Schüpbach, Sabine Weber Zaugg 
(Zentrum für Bewegungsstörungen, Neurologische Klinik und Poliklinik, Universität Bern) 
Zürich (University Hospital and University of Zurich): Hans H. Jung, Jens A. Petersen, Maria Ligon-Auer, Violeta Mihaylova 
 
U.K. 
Aberdeen (NHS Grampian Clinical Genetics Centre & University of Aberdeen): Lorna Downie, Roisin Jack, Kirsty Matheson, Zosia 
Miedzybrodzka, Daniela Rae, Sheila A Simpson, Fiona Summers, Alexandra Ure, Vivien Vaughan 
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Birmingham (The Barberry Centre, Dept of Psychiatry): Shahbana Akhtar, Jenny Crooks, Adrienne Curtis, Jenny de Souza (Keylock), John 
Piedad, Hugh Rickards, Jan Wright  
Bristol (North Bristol NHs Trust, Southmead hospital): Elizabeth Coulthard, Louise Gethin, Beverley Hayward, Kasia Sieradzan, Abigail 
Wright 
Cambridge (Cambridge Centre for Brain Repair, Forvie Site): Roger A. Barker, Deidre O’Keefe, Anna Gerrtiz (nee Di Pietro), Kate Fisher, 
Anna Goodman, Susan Hill, Sarah Mason, Rachel Swain, Natalie Valle Guzman 
Cardiff (Schools of Medicine and Biosciences, Cardiff University): Monica Busse, Cynthia Butcher, Stephen Dunnett, Catherine Clenaghan, 
Ruth Fullam, Sarah Hunt, Lesley Jones, Una Jones, Hanan Khalil, Sara Minster,  Michael Owen, Kathleen Price, Jenny Townhill,  Anne Rosser 
Dundee (Scottish Huntington's Association, Ninewells Hospital): David Goudie, Lindsay Buchanan, Paula McFadyen, Alison Tonner, Anne-
Marie Taylor 
Edinburgh (SE Scotland Genetic Service, Western General Hospital): Maureen Edwards, Carrie Ho (Scottish Huntington´s Association), 
Marie McGill, Mary Porteous, Pauline Pearson 
Exeter (Department of Neurology Royal Devon and Exeter Foundation Trust Hospital): Timothy Harrower, Sarah Irvine 
Fife (Scottish Huntington's Association Whyteman's Brae Hospital): Peter Brockie, Jillian Foster, Nicola Johns, Sue McKenzie, Jean 
Rothery, Gareth Thomas, Shona Yates 
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Glasgow (Glasgow HD Management Clinic, Southern General Hospital): Catherine Deith, Jane Ireland, Stuart Ritchie  
Gloucester (Department of Neurology Gloucestershire Royal Hospital): Pauline Brown, Liz Burrows, Amy Fletcher, Alison Harding, Fiona 
Laver, Mark Silva, Aileen Thomson  
Hull (Castle Hill Hospital): Carol Chu, Carole Evans, Deena Gallentree, Stephanie Hamer, Alison Kraus, Ivana Markova, Ashok Raman 
Leeds (Chapel Allerton Hospital, Department of Clinical Genetics): Jeremy Cosgrove, Deena Gallantree, Stephanie Hamer, Emma Hobson, 
Stuart Jamieson , Alison Kraus, Mandy Longthorpe, Ivana Markova, Hannah Musgrave, Caroline Peacy, Ashok Raman, Liz Rowett, Jean 
Toscano, Sue Wild, Pam Yardumian  
Leicester (Leicestershire Partnership Trust, Mill Lodge): Carole Clayton, Heather Dipple, Dawn Freire-Patino, Caroline Hallam, Julia 
Middleton   
London (St. Georges-Hospital): Uruj Anjum, Jan Coebergh, Charlotte Eddy, Nayana Lahiri, Meriel McEntagart, Michael Patton, Maria 
Peterson, Sarah Rose  
London (Guy's Hospital): Thomasin Andrews, Andrew Dougherty, Charlotte Golding, Fred Kavalier, Hana Laing, Alison Lashwood, Dene 
Robertson, Deborah Ruddy, Alastair Santhouse, Anna Whaite 
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London (The National Hospital for Neurology and Neurosurgery): Thomasin Andrews, Stefanie Brown, Stefania Bruno, Elvina Chu, Karen 
Doherty, Charlotte Golding, Salman Haider, Davina Hensman, Nayana Lahiri, Monica Lewis, Marianne Novak, Aakta Patel, Nicola Robertson, 
Elisabeth Rosser, Sarah Tabrizi, Rachel Taylor, Thomas Warner, Edward Wild  
Manchester (Genetic Medicine, University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester 
University Hospitals NHS Foundation Trust): Natalie Arran, Judith Bek, Jenny Callaghan, David Craufurd, Ruth Fullam, Marianne Hare, Liz 
Howard, Susan Huson, Liz Johnson, Mary Jones, Ashok Krishnamoorthy, Helen Murphy, Emma Oughton, Lucy Partington-Jones, Dawn 
Rogers, Andrea Sollom, Julie Snowden, Cheryl Stopford, Jennifer Thompson, Iris Trender-Gerhard, Nichola Verstraelen (formerly Ritchie), 
Leann Westmoreland  
Newcastle-upon-Tyne (Centre for Life, Institute of Medical Genetics): Ginette Cass, Lynn Davidson, Jill Davison, Neil Fullerton, Katrina 
Holmes, Suresh Komati, Sharon McDonnell, Zeid Mohammed, Karen Morgan, Lois Savage, Baldev Singh, Josh Wood 
Northampton (St Andrew’s Healthcare): Elvina Chu, Caroline Knight, Mari O’Neill, Debasish Das Purkayastha 
Oxford (Oxford University Hospitals NHS Trust, Dept. of Neurosciences, University of Oxford): Andrea H Nemeth, Gill Siuda, Ruth 
Valentine, Kathryn Dixon, Richard Armstrong 
Plymouth (Plymouth Huntington Disease Service, Mount Gould Hospital): David Harrison, Max Hughes, Sandra Large, John O Donovan, 
Amy Palmer, Andrew Parkinson, Beverley Soltysiak, Leanne Timings, Josh Williams  
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Preston (Neurology Department, Preston Royal Hospital): Marianne Hare, Tahir Majeed, Nicola Verstraelen (Ritchie)  
Sheffield (The Royal Hallamshire Hospital– Sheffield Children’s Hospital): Oliver Bandmann, Alyson Bradbury, Helen Fairtlough, Kay 
Fillingham, Isabella Foustanos, Paul Gill, Mbombe Kazoka, Kirsty O’Donovan, Louise Nevitt, Nadia Peppa, Oliver Quarrell, Cat Taylor, 
Katherine Tidswell, Kirsty O’Donovan 
Swindon (Victoria Centre, Great Western Hospital): Lesley Gowers, Kingsley Powell, Pamela Bethwaite, Rachel Edwards, Kathleen Fuller, 
Michelle Phillips 
 
EHDN’s associate site in Singapore: 
National Neuroscience Institute Singapore: Louis Tan, Jean-Marc Burgunder, Puay Ngoh Lau, Emmanuel Pica 
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Table 1 Group characteristics 
 PreA 
 
PreB Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 
Gender (m/f) baseline visita 118 / 219 108 / 143* 423 / 365* 357 / 386 234 / 239 25 / 46 1 / 5 
Gender (m/f) last visita 78/162 69/115* 250/238* 352/316 384/399 120/150 13/23 
Number of visitsb 3.8 (1-8) 4.2 (1-12) 3.8 (1-10) 3.6 (1-9) 3.1 (1-9) 2.6 (1-7) 2.0 (1-2) 
Age (years)c 36 (9)* 42 (10)* 48 (11)* 52 (11)* 54 (11)* 55 (10) 58 (11) 
Education (years)c 13 (4) 13 (4)* 12 (4)* 11 (4)* 11 (3)* 10 (4) 11 (4) 
CAG lengthc 41 (2.0)* 44 (2.6)* 44 (2.8) 44 (2.8) 44 (2.6) 44 (2.7) 43 (3.7) 
PreA: pre-motormanifest A; PreB: pre-motormanifest B 
atotal number; significant difference between the groups marked with * 
bParticipants were grouped based on baseline characteristics; mean (range) 
cmean (standard deviation); significant difference between the groups marked with * 
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Table 2 Results of the linear mixed effects models; comparing subsequent disease stages per cognitive task 
 N PreA – PreB 
 
PreB – Stg1 Stg1 – Stg2 Stg2 – Stg3 Stg3 – Stg4 Stg4 – Stg5 
Phonemic verbal fluencya 
 
2548 1.66 (0.55) 4.03 (0.40)* 3.16 (0.26)* 3.56 (0.25)* 2.46 (0.42)* 0.39 (1.40) 
Stroop Colora 
 
2554 5.08 (0.70)* 4.56 (0.51)* 6.40 (0.33)* 6.56 (0.32)* 5.20 (0.53)* 5.25 (1.62)  
Stroop Worda 
 
2526 5.35 (0.97)* 7.00 (0.71)* 8.34 (0.45)* 9.60 (0.42)* 8.41 (0.71)* 7.49 (2.21)  
Stroop Interferencea 
 
2540 3.50 (0.52)* 3.81 (0.39)* 4.10 (0.25)* 3.90 (0.24)* 3.78 (0.42)* 1.57 (1.37) 
Symbol Digit Modalities Testa 
 
2521 3.49 (0.49)* 4.59 (0.36)* 4.02 (0.23)* 4.29 (0.22)* 2.76 (0.40)* 1.71 (1.53) 
Categorical Fluencya 1410 2.18 (0.51)* 3.50 (0.42)* 2.27 (0.27)* 2.42 (0.25)* 2.02 (0.42)* 0.69 (1.44) 
PreA: pre-motormanifst A; PreB: pre-motormanifest B; Stg1: disease stage 1; Stg2: disease stage 2; Stg3: disease stage 3; Stg4: disease stage 4; Stg5: disease stage 5 
 a Estimate (SE); * sig < 0.008 
Cognitive decline in HD 
43 
 
Cognitive decline in HD 
44 
 
Table 3 Comparing CAG length 42 with 44 on cognitive task performance based on longitudinal model 
 N For age 30 For age 45 For age 60 
Phenomic verbal fluencya 
 
2548 2.39 (0.29)* 5.75 (0.22)* 6.77 (0.36)* 
Stroop Colora 
 
2554 4.05 (0.37)* 9.37 (0.28)* 12.26 (0.46)* 
Stroop Worda 
 
2526 5.09 (0.50)* 11.90 (0.36)* 16.03 (0.60)* 
Stroop Interferencea 
 
2540 2.70 (0.27)* 5.63 (0.20)* 6.84 (0.34)* 
Symbol Digit Modalities Testa 
 
2521 4.08 (0.27)* 8.09 (0.21)* 8.95 (0.34)* 
Categorical Fluencya 1410 1.80 (0.22)* 2.88 (0.15)* 2.83 (0.23)* 
 a Estimate (SE); * sig < 0.01. 
 
